Comparative Pharmacology
Head-to-head clinical analysis: AEROLATE JR versus DILOR 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROLATE JR versus DILOR 400.
AEROLATE JR vs DILOR-400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular cAMP and cGMP, resulting in bronchodilation and vasodilation.
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.
None Documented
None Documented
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
3.1 hours (terminal elimination half-life; may increase in hepatic impairment or congestive heart failure)
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
Renal (70% unchanged), hepatic metabolism (30%)
Category C
Category C
Bronchodilator
Bronchodilator